{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:30:13Z","timestamp":1789475413243,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"DOI":"10.1007\/s12664-025-01767-7","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:25:03Z","timestamp":1750231503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative versus adjuvant chemotherapy in carcinoma stomach\u2014A retrospective propensity-matched analysis"],"prefix":"10.1007","author":[{"given":"Archana","family":"Elangovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-5056","authenticated-orcid":false,"given":"Prasanth","family":"Penumadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Sreekumaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramanian","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"1767_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.\u00a02021;71:209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"1767_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/gutjnl-2019-320234","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69:823\u20139.","journal-title":"Gut"},{"key":"1767_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13401","author":"S Kumar","year":"2020","unstructured":"Kumar S, Seshadri RA, Trivadi SG, Dhanushkodi M, Ellusamy HR. Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis. Asia Pac J Clin Oncol. 2020;16:e252\u20136.\u00a0https:\/\/doi.org\/10.1111\/ajco.13401.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1767_CR4","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.3748\/wjg.v21.i40.11428","volume":"21","author":"S Pernot","year":"2015","unstructured":"Pernot S. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21:11428.","journal-title":"World J Gastroenterol"},{"key":"1767_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1767_CR6","doi-asserted-by":"crossref","unstructured":"Al-Batran S-E, Pauligk C, Homann N, et al. Docetaxel, oxaliplatin, and fluorouracil\/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF\/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: the multicenter, randomized phase 3 flot4 trial (German gastric group at AIO). Annals of Oncology. 2017;28:iii152\u2013iii153.","DOI":"10.1093\/annonc\/mdx302.007"},{"key":"1767_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"Y-J Bang","year":"2012","unstructured":"Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (classic): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321.","journal-title":"The Lancet"},{"key":"1767_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01136-7","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.\u00a0Gastric Cancer. 2021;24:492\u2013502.\u00a0https:\/\/doi.org\/10.1007\/s10120-020-01136-7.","journal-title":"Gastric Cancer"},{"key":"1767_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.2017.35.4_suppl.119","volume":"35","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Chen H-C, Wang X, et al. Recurrence patterns of gastric cancer in the era of preoperative therapy. J Clin Oncol. 2017;35:119.","journal-title":"J Clin Oncol"},{"key":"1767_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1046\/j.1365-2168.2000.01360.x","volume":"87","author":"CH Yoo","year":"2000","unstructured":"Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236\u201342.","journal-title":"Br J Surg"},{"key":"1767_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718556","author":"W Xu","year":"2021","unstructured":"Xu W, Wang L, Yan C, et al. Neoadjuvant chemotherapy versus direct surgery for locally advanced gastric cancer with serosal invasion (cT4NxM0): a propensity score-matched analysis.Front Oncol. 2021;11:718556.\u00a0https:\/\/doi.org\/10.3389\/fonc.2021.718556.","journal-title":"Front Oncol"},{"key":"1767_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02914","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer.\u00a0J Clin Oncol. 2021;39:2903\u201313.\u00a0https:\/\/doi.org\/10.1200\/jco.20.02914.","journal-title":"J Clin Oncol"},{"key":"1767_CR13","doi-asserted-by":"publisher","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.\u00a0https:\/\/doi.org\/10.1016\/s1470-2045(21)00297-7.","DOI":"10.1016\/s1470-2045(21)00297-7"},{"key":"1767_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1245\/s10434-013-3356-0","volume":"21","author":"DD Smith","year":"2013","unstructured":"Smith DD, Nelson RA, Schwarz RE. A comparison of five competing lymph node staging schemes in a cohort of resectable gastric cancer patients. Ann Surg Oncol. 2013;21:875\u201382.","journal-title":"Ann Surg Oncol"},{"key":"1767_CR15","first-page":"20","volume":"17","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Zeng X, Zhang C, et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy.\u00a0World J Surg Oncol. 2022;20:261.","journal-title":"World Journal of Surgical Oncology"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-025-01767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-025-01767-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-025-01767-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:25:05Z","timestamp":1750231505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-025-01767-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":15,"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1007\/s12664-025-01767-7","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AE, PP, BD, NSN and BA declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Ethics Committee, JIPMER, India, approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable given the retrospective nature of the study. A waiver of consent was approved by the Institutional Ethics Committee, JIPMER, India.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}